|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2013 (US)
2009 (Europe)
|
|
gptkbp:ATCCode
|
N03AF04
|
|
gptkbp:bioavailability
|
>90%
|
|
gptkbp:brand
|
gptkb:Aptiom
gptkb:Zebinix
|
|
gptkbp:CASNumber
|
236395-14-5
|
|
gptkbp:chemicalFormula
|
C16H15N2NaO3
|
|
gptkbp:contraindication
|
hypersensitivity to eslicarbazepine
|
|
gptkbp:developedBy
|
gptkb:BIAL
|
|
gptkbp:drugClass
|
dibenzazepine derivative
|
|
gptkbp:eliminationHalfLife
|
13-20 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
eslicarbazepine acetate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
voltage-gated sodium channel blocker
|
|
gptkbp:metabolism
|
eslicarbazepine
|
|
gptkbp:molecularWeight
|
318.29 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
~40%
|
|
gptkbp:PubChem_CID
|
8012637
9837246
|
|
gptkbp:relatedTo
|
gptkb:carbamazepine
gptkb:oxcarbazepine
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
hyponatremia
somnolence
|
|
gptkbp:UNII
|
7E4PHP5N1D
|
|
gptkbp:usedFor
|
partial-onset seizures
|
|
gptkbp:bfsParent
|
gptkb:Aptiom
|
|
gptkbp:bfsLayer
|
7
|